LENZ Therapeutics, Inc. 8-K

What Happened

• On January 7, 2026, LENZ Therapeutics, Inc. announced preliminary, unaudited financial results for the three months ended December 31, 2025 via a press release. The company emphasized these figures are preliminary, have not been audited and may change upon completion of its accounting and annual audit procedures. The press release was furnished as Exhibit 99.1 to the Form 8-K. The report was signed by Daniel Chevallard, Chief Financial Officer.

Key Details

• Date of disclosure: January 7, 2026 (Form 8-K filing).
• Period covered: three months ended December 31, 2025.
• Results described as preliminary and unaudited, subject to adjustment after audit and accounting close.
• Press release furnished as Exhibit 99.1; Form 8-K notes additional disclosures would be required for a full understanding of the company’s financial position.

Why It Matters

• Preliminary, unaudited quarterly results can move investor expectations but are subject to change; investors should treat these figures as provisional until audited results and any required supplemental disclosures are published.
• Watch for the company’s finalized financial statements (e.g., in its annual report or amended filings) for confirmed earnings, revenue and other metrics before making investment decisions.